Quantcast

Kinexus Bioinformatics Launches Online Proteomics DataBase

July 13, 2011

Over 1.5 million measurements of protein expression and phosphorylation
now available at new KiNET-Antibody Microarray website

VANCOUVER, July 13, 2011 /PRNewswire/ – Kinexus Bioinformatics Corporation, a
world-leader in molecular intelligence research, announced a major
expansion in its KiNET DataBank (http://www.kinexus.ca/ourServices/kinet/kinet.html) for the study of cell communication systems with the launch of the
KiNET-Antibody Microarray (KiNET-AM) website. This open access, online
resource for the scientific community features over 1.5 million
measurements of the levels and phosphorylation status of over 400
distinct protein kinases and their targets in over 2000 tissue and cell
specimens. All of the data was generated in-house at Kinexus with its
proprietary Kinex(TM) antibody microarrays with biological samples
provided over the last 5 years by over 600 academic and industrial
laboratories from around the globe. KiNET-AM complements the
KiNET-Immunoblotting (KiNET-IB) DataBase that was first launched in
2005. KiNET-IB contains over 200,000 measurements of protein
phosphorylation and expression as determined with Kinexus’ Kinetworks(TM)
Multi-immunoblotting technology. Together, KiNET-AM and KiNET-IB
provide the world’s largest repository of semi-quantitative proteomics
data with antibody probes.

The human genome encodes at least 516 protein kinases that regulate each
other and ~22,500 other diverse proteins to coordinate all cellular
operations in signaling networks. Kinases function by tagging target
proteins at specific locations with phosphates (P-sites), a process
known as phosphorylation. These P-sites serve as molecular on/off
switches. Protein kinases are well recognized by the pharmaceutical and
biotech industry as highly productive targets for drug development with
application to over 400 human diseases. Cancer, diabetes, Alzheimer’s
disease are just a few of many examples of disorders that arise from
cellular miscommunication.

The KiNET DataBank is one of several open access initiatives from
Kinexus to promote the advancement of biomedical research into cell
signaling systems for disease biomarker identification and development
of specific therapeutic drugs to enable personalized medicine delivery.
Earlier this year, Kinexus also updated its PhosphoNET KnowledgeBase (www.phosphonet.ca) to feature data on over 93,000 experimentally-confirmed human P-sites
and 560,000 additional predicted P-sites, including prediction of which
kinases individually target each of these P-sites, and their
evolutionary conservation in over 20 other diverse organisms.

“While all human cells carry the same genes, the production of proteins
from these genes and the subsequent regulation of proteins by
phosphorylation is markedly different and constantly changing in the
various cell types found in the tissues and organs of the body”
commented Dr. Steven Pelech, President and Chief Scientific Officer of
Kinexus and a professor in the Department of Medicine at the University
of British Columbia. “Monitoring the expression and phosphorylation of
specific proteins is immensely more challenging than genomic analyses,
but is essential for guiding biomedical researchers in more fruitful
directions to define biomarkers for disease diagnosis and kinase drug
targets for development of new treatments.”

For 12 years, Kinexus has been a unique provider of proteomics services
to academic and industrial laboratories to track protein kinases and
their phosphoprotein targets in experimental tissue and cell specimens.
The company has developed a diverse panel of microarrays and
complementary technologies that can monitor the presence and activity
levels of hundreds of kinases and their targets, their interactions,
and the effects of promising drug candidates. The application of this
knowledge positions Kinexus and its clients for improved disease
diagnosis and personalized drug therapies to improve human health.

SOURCE Kinexus Bioinformatics Corporation


Source: newswire



comments powered by Disqus